Key result
Propafenone was superior to disopyramide in reducing the median number of premature ventricular complexes and had fewer side effects.
Why the study?
Does propafenone improve PVC suppression compared to disopyramide in patients with symptomatic premature ventricular complexes?
RCT (n=38)
Single-blind
Randomized
Does propafenone improve PVC suppression compared to disopyramide in patients with symptomatic premature ventricular complexes?
Propafenone 150 mg four times daily is superior to disopyramide 100 mg four times daily in suppressing symptomatic PVCs and is associated with fewer side effects.
Answers are grounded in this paper and cite their sources.
Supports preferring propafenone to disopyramide for symptomatic PVCs; strengthens RCT evidence for class Ic over class Ia agents.
The efficacy and safety of propafenone, 150 mg four times daily, were compared with those of disopyramide, 100 mg four times daily, in a randomized single-blind, cross-over study in 38 patients with symptomatic premature ventricular complexes (PVCs). The 24-hour ambulatory ECG, employed for assessing antiarrhythmic efficacy, was analyzed blindly. The median reduction in the number of PVCs was higher with propafenone than with disopyramide (91.4% vs. 63.5%, respectively, p less than 0.01). A reduction of at least 80% was achieved by propafenone in 22 (59%) and by disopyramide in 16 patients (43%) (NS). Ventricular tachycardias (VTs) were abolished by propafenone in eight out of 11, and by disopyramide in five out of nine patients with VTs (NS) a possible proarrhythmic effect was seen in three patients during disopyramide and in one patient during propafenone treatment. Micturition disturbances (p less than 0.001) and a dry mouth (p less than 0.01) were more commonly associated with disopyramide than with propafenone. In conclusion, in the given dosages, propafenone was superior to disopyramide in suppressing PVCs and had fewer side-effects.
No takes yet. Share an insight, caveat, or question.
Jonason et al. (1988) conducted an RCT in Symptomatic premature ventricular complexes (PVCs) (n=38). Propafenone vs. Disopyramide, 100 mg four times daily was evaluated on Median reduction in the number of PVCs (p=<0.01). Propafenone was superior to disopyramide in reducing the median number of premature ventricular complexes and had fewer side effects.
Synapse has enriched 10 related papers. Consider them for comparative context: